Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
Date:3/3/2010

Revenue from our Base Medical Products declined by 7% in the fourth quarter of 2009 as compared to the fourth quarter of 2008 and by 6% as compared to the third quarter of 2009. Excluding the impact of foreign currency changes, revenue would have declined by 9% and 7%, respectively. Revenue for these products for the year ended December 31, 2009 declined by 9% as compared to the year ended December 31, 2008. Excluding the impact of foreign currency changes between the periods, the decline in revenue would have been 8%.

The decline in our Base Medical Products sales in 2009 was due primarily to lower sales of medical device components to other third party medical device manufacturers. We believe this aspect of our Base Medical Product sales were significantly impacted in 2009 by certain customers that unexpectedly postponed or cancelled orders, or that implemented inventory reduction programs in response to changing economic and credit market conditions. In addition, we believe our transfer of manufacturing of certain surgical needle component products to our facility in Aguadilla, Puerto Rico from our facility in Syracuse, New York may have contributed to more volatile customer ordering patterns in 2009 as compared to prior years. While we currently expect that certain of our customers may increase their order levels in 2010, there can be no assurance that we will record sales of surgical needles to these customers at levels observed in prior periods.
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Angiotech Pharmaceuticals Announces Conference Call and Webcast
2. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
3. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
4. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
5. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
6. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
7. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
8. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
9. Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
10. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
11. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Houston, TX (PRWEB) December 17, 2014 ... marketing and administration for Stoller Group. In this position, ... Stoller Group, on administrative matters, develop marketing strategy and ... and services. , “Achim has tremendous knowledge and ... president of Stoller Group. “His experience and innovative thinking ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 This ... Global Quartz Tubing industry. For an overview analysis, ... classification, application, industry chain structure, industry overview, policy ... quartz tubing industry has witnessed rapid development ... number of acquisitions. This report mentions quartz tubing ...
(Date:12/17/2014)... CA (PRWEB) December 17, 2014 Audacity, ... activation agency and member of the Huntsworth Health Group, ... to its executive team. In her role, Gonzales will ... , “We are incredibly honored to welcome a talent ... Chief and CEO, Gaëtan Fraikin. “She is a proven ...
(Date:12/17/2014)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), ... commercialization of innovative therapeutics addressing cancer and other unmet ... commercial focus on China , today ... meeting with the U.S. Food and Drug Administration (FDA) ... 2015.  During this meeting the Company will seek guidance ...
Breaking Biology Technology:Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 22020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
... a Conference Call Today To Discuss the Data and Ongoing ... Clinical Development Programs, ... ) announced today top-line data from its,SB-509-601 clinical trial, one of ... develop SB-509 for diabetic,neuropathy (DN). The data demonstrate that repeat administration ...
... HDL functionality are distinguishing factors, ... LA, Nov. 10 /PRNewswire-FirstCall/ - Resverlogix Corp.,("Resverlogix") ... scientific data,was presented in an oral presentation ... American Heart Association Scientific Meeting. The,presentation titled ...
... of transport of key amyloid marker from ... Nov. 10 /PRNewswire-FirstCall/ - Resverlogix Corp.,("Resverlogix") (TSX:RVX) announced ... first in class ApoA-I/Prebeta-HDL elevating drug, in a ... that treatment with RVX-208,resulted in a positive trend ...
Cached Biology Technology:Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 2Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 3Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 4Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 5Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 6RVX-208 Data Demonstrates Increase in Functional HDL Particles 2RVX-208 Data Demonstrates Increase in Functional HDL Particles 3RVX-208 Data Demonstrates Increase in Functional HDL Particles 4RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease 2RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease 3RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease 4
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:12/4/2014)... 3, 2014  Crossmatch™, a leading provider of ... DigitalPersona ® Pro Enterprise software and U.are.U ... throughout First Bank branch locations in ... and Virginia. First Bank, a progressive community ... North Carolina , selected the Crossmatch biometrics-based ...
(Date:12/3/2014)... Ariz. , Dec. 2, 2014 As ... hand readers, Inception Technologies is pleased to announce the ... easier for customers to collect the workforce data that ... problems that have been left by existing readers. Many ... user interface, connectivity and modern technology. Older models force ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2
... on the rise and more than 120 countries now ... right to create a new, specialized global environmental agency, ... a keynote address to government ministers meeting Tuesday in ... Minister of Malaysia and former co-chair of the UN ...
... science program for Euroscience Open Forum 2012 (ESOF 2012) was ... 2012 will take place in Dublin this year from 11th ... in Europe, will be held in the heart of the ... ESOF is an interdisciplinary, pan-European meeting, held under the auspices ...
... Vicious, winner-take-all competition in nature is an essential pillar ... people have about how, or whether, to teach the ... science and religion are in deliberate opposition, like two ... and practicing Catholic Kenneth Miller teaches evolution, he also ...
Cached Biology News:Create effective new global environmental agency, ministers urged 2Create effective new global environmental agency, ministers urged 3Science Program announced for Euroscience Open Forum 2012 in Dublin 2Science Program announced for Euroscience Open Forum 2012 in Dublin 3Science Program announced for Euroscience Open Forum 2012 in Dublin 4Science Program announced for Euroscience Open Forum 2012 in Dublin 5Teaching science to the religious? Focus on how theories develop 2Teaching science to the religious? Focus on how theories develop 3
...
...
... The newest member of Wyatt Technology's ... fits inside of your high temperature chromatograph ... scattering data from thermoplastic polymers. The HTmD ... any Waters 150C, PL220C or Alliance 2000 ...
...
Biology Products: